Status:
WITHDRAWN
T-cell Based Immunotherapy for Head and Neck Cancer
Lead Sponsor:
Inge Marie Svane
Conditions:
Squamous Cell Carcinoma
Head and Neck Cancer
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The aim of this study is to investigate the toxicity and immune response of therapy with tumor infiltrating lymphocytes as adjuvant treatment for head and neck cancer after primary operation and radio...
Eligibility Criteria
Inclusion
- Patients with histological proven squamous cell carcinoma T3 or more in the oral cavity planned for primary surgery. Performance Status 0 to 1. Acceptable CBC and blood chemistry results. Acceptable organ functions.
Exclusion
- Patients with a history of any other malignancies less than five years ago. Brain metastases. Other significant illness including severe allergy, asthma, DM, angina pectoris, congestive heart failure, chronic infections, or active autoimmune disease. Treatment with immune suppressive drugs, experimental drugs, or antineoplastic drugs.
Key Trial Info
Start Date :
June 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00937300
Start Date
June 1 2009
End Date
June 1 2011
Last Update
November 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Oncology, Copenhagen University Hospital, Herlev
Herlev, Denmark, 2730